Viyash completes BioForLife and adds 128 KL API capacity

Viyash Scientific Limited completed the BioForLife acquisition on 1 October 2026 and is adding 128 KL of active pharmaceutical ingredient capacity, alongside a companion-animal tablet facility targeted for Q1 FY28 and an oncology research centre. The programme combines Italian veterinary-market access with formulation development, internal manufacturing and backward integration.

What did Viyash complete in Italy?

Viyash completed the acquisition of BioForLife in Italy on 1 October 2026, after executing the share purchase agreement on 21 July 2026. The company says the acquisition aligns with its companion-animal strategy and provides access to a large companion-animal market in Italy.

BioForLife brings a companion-animal portfolio of 85 to 90 products that Viyash says can be extended to other core markets. Its salesforce has coverage of 85% of veterinary clinics in Italy, providing the stated route for Viyash to launch its global pipeline in the country and add talent locally.

Viyash has identified integration of BioForLife and cross-selling Alivira and BioForLife products as its first priority in Animal Health Formulations. That makes the acquisition a commercial-platform addition as well as a portfolio expansion, with the 85% clinic coverage forming the disclosed distribution base for the plan.

The presentation does not disclose an acquisition price, BioForLife revenue, or a sales target from the deal. It does distinguish the completed 1 October 2026 transaction from the operating projects still under development, including the Ambernath facility planned for Q1 FY28.

How is Viyash building companion-animal manufacturing?

Viyash has initiated capital expenditure for a dedicated companion-animal tablet facility at Ambernath, with commissioning and the start of production expected in Q1 FY28. The company describes the project as providing day-one launch readiness through in-house manufacturing for its companion-animal pipeline.

The Ambernath project is intended to support internal production of companion-animal products, while BioForLife supplies an Italian commercial platform with 85 to 90 products. Viyash separately lists day-one launches of companion-animal new products as an Animal Health Formulations priority, linking the planned plant to product introductions.

The companion-animal programme follows higher animal-health research and development investment reported with Q2 FY27 results. Viyash specifically attributed the increase in animal-health research and development spending to support new products for companion animals, although the presentation does not provide a separate spending amount.

Geographic expansion is another stated priority for Animal Health Formulations: Viyash says Vietnam expansion has been initiated and acquisitions may be used to fill portfolio gaps and add market access. The immediate disclosed operating milestone, however, is the expected Q1 FY28 commissioning and production start at Ambernath.

How is Viyash expanding oncology and API capacity?

Viyash is establishing a finished-dosage-form research and development centre for oncology at Jeedimetla, Hyderabad, to connect active pharmaceutical ingredient, or API, development with finished-product development. The centre is designed to run pilot-scale batches and includes isolator-based containment for high-potent molecules.

The Jeedimetla project supports Viyash's stated plan to build an end-to-end oncology platform in human formulations. Its disclosed value chain runs from API development and manufacturing through finished-product development and manufacturing, with the new centre positioned at the finished-product development stage.

Separately, Viyash is adding 128 KL of API capacity through a new manufacturing block at Viyash-IV in Nalgonda. The company says all necessary approvals have been received and that the block will support rising demand for select APIs and backward integration.

The Nalgonda block fits Viyash's API and contract development and manufacturing organisation, or CDMO, priorities. These include developing complex human-health molecules and a full animal-health API portfolio, winning new customers for key molecules, supplying APIs to its own formulations, and pursuing CDMO opportunities with partners.

What do Viyash's recent segment revenues show?

Viyash reported global sales of Rs 1,931.4 crore in H1 FY27, up 18% from Rs 1,642.4 crore in H1 FY26. Formulations grew faster than APIs in the six-month period, providing the reported revenue backdrop to investment in companion-animal products, human formulations and API supply.

In H1 FY27, formulations revenue increased 26%, compared with 8% growth in APIs. Within formulations, India grew 49%, emerging markets 39%, Europe 16% and the United States 15% year on year, showing growth across four reported regions rather than in a single market.

The Q2 FY27 comparison also showed faster formulation growth. Formulations revenue was Rs 558.7 crore, up 19% from Rs 468.7 crore in Q2 FY26, while API revenue was Rs 415.4 crore, up 12% from Rs 372.1 crore in the prior-year quarter.

Viyash's reported sales mix therefore covers both parts of the expansion programme: formulation development through companion-animal and oncology initiatives, and API supply through the 128 KL Nalgonda block. The presentation does not quantify revenue expected from any individual project or state when the Nalgonda block will begin production.

Conclusion

The disclosures show a multi-part expansion programme: BioForLife adds an Italian companion-animal portfolio of 85 to 90 products and 85% veterinary-clinic coverage, Ambernath is intended to provide tablet production, Jeedimetla supports high-potent oncology development, and Nalgonda adds 128 KL of API capacity. H1 FY27 formulation revenue growth of 26%, against 8% for APIs, is the reported commercial context.

The next disclosed operating milestone is expected commissioning and production at Ambernath in Q1 FY28. Other matters to watch are the integration of BioForLife and Alivira cross-selling, the initiated Vietnam expansion, progress on the end-to-end oncology plan, and the still-undisclosed capital cost, revenue contribution and production timetable for the Nalgonda block.